|
|
Post by greg on Mar 14, 2016 19:30:45 GMT -5
Absent a cash infusion in the relatively near future, MannKind essentially transitions into oblivion. This is an objective indisputable fact.
Events on the ground and Matt's tone (and comments) in the latest conference call very strongly suggest that the company is here to stay...
The addition of the CCO is clearly a positive. If you were a VP at biotech powerhouse Amgen, undoubtedly making big bucks, would you leave to join a tiny biotech that was going out of business in a matter of months. Castagna was most certainly made privy to critical information that gave him the confidence to jump ship.
Matt all but poo pooed the idea of having to tap into the Mann credit facility. He also noted the possibility of international transaction(s). Moreover, he took strong exception to Olson's characterization of Sanofi having invested heavily on DTC marketing. All of this suggests that some monies are soon forthcoming. As Matt has indicated previously, the foreign players stepped forward literally days after Sanofi's termination notice. This means their interest persisted from at least mid-2014, so the probability is that a deal or two or three is pending, awaiting the full transfer of Afrezza from Sanofi to MNKD. Matt's objection to Olson's characterization, meantime, is strongly indicative of the probability that negotiations are ongoing to extract some money from Sanofi for its not living up to its legal obligations to use all reasonable efforts to sell Afrezza.
All things considered, I think MNKD stock offers superb risk reward possibilities. Any announcement of a cash infusion, eliminating the fear of a near-term bankruptcy filing, would have the shares soaring. As such, I also think the notion of trading the stock, to take profits for those who bought at the lows, is rather silly.
|
|
|
|
Post by kball on Mar 14, 2016 19:44:48 GMT -5
Absent a cash infusion in the relatively near future, MannKind essentially transitions into oblivion. This is an objective indisputable fact. Events on the ground and Matt's tone (and comments) in the latest conference call very strongly suggest that the company is here to stay...
The addition of the CCO is clearly a positive. If you were a VP at biotech powerhouse Amgen, undoubtedly making big bucks, would you leave to join a tiny biotech that was going out of business in a matter of months. Castagna was most certainly made privy to critical information that gave him the confidence to jump ship.Matt all but poo pooed the idea of having to tap into the Mann credit facility. He also noted the possibility of international transaction(s). Moreover, he took strong exception to Olson's characterization of Sanofi having invested heavily on DTC marketing. All of this suggests that some monies are soon forthcoming. As Matt has indicated previously, the foreign players stepped forward literally days after Sanofi's termination notice. This means their interest persisted from at least mid-2014, so the probability is that a deal or two or three is pending, awaiting the full transfer of Afrezza from Sanofi to MNKD. Matt's objection to Olson's characterization, meantime, is strongly indicative of the probability that negotiations are ongoing to extract some money from Sanofi for its not living up to its legal obligations to use all reasonable efforts to sell Afrezza. All things considered, I think MNKD stock offers superb risk reward possibilities. Any announcement of a cash infusion, eliminating the fear of a near-term bankruptcy filing, would have the shares soaring. As such, I also think the notion of trading the stock, to take profits for those who bought at the lows, is rather silly. Was anyone else thrilled the guy made it from announcement to conference call after that whole DeSisto fiasco? I was |
|
|
|
Post by taylor810dn on Mar 15, 2016 8:17:01 GMT -5
It would be silly to get left on the sidelines, however MNKD's past has shown some patterns, and for the first time in a year I made a swing trade yesterday based on expectations, I sold half my position at $1.50 and bought it back in AH for $1.19, I didn't take profits but I made a significant increase in my share count. I have been down too long to not take what MNKD will give, a few more trades like that and my entire position will be above water. GLTA.
|
|
|
|
Post by hawaiiguy42 on Mar 15, 2016 8:33:39 GMT -5
Look at the Amgen stock chart while the he was the CCO. I would say he's a very good fit for Mannkind/Afrezza, etc.
|
|
|
|
Post by mindovermatter on Mar 15, 2016 8:41:48 GMT -5
Look at the Amgen stock chart while the he was the CCO. I would say he's a very good fit for Mannkind/Afrezza, etc. Do you really believe he was a catalyst for Amgen's stock price, a company with more than 17,000 employees? |
|
|
|
Post by alethea on Mar 15, 2016 12:45:36 GMT -5
Absent a cash infusion in the relatively near future, MannKind essentially transitions into oblivion. This is an objective indisputable fact. Events on the ground and Matt's tone (and comments) in the latest conference call very strongly suggest that the company is here to stay...The addition of the CCO is clearly a positive. If you were a VP at biotech powerhouse Amgen, undoubtedly making big bucks, would you leave to join a tiny biotech that was going out of business in a matter of months. Castagna was most certainly made privy to critical information that gave him the confidence to jump ship. Matt all but poo pooed the idea of having to tap into the Mann credit facility. He also noted the possibility of international transaction(s). Moreover, he took strong exception to Olson's characterization of Sanofi having invested heavily on DTC marketing. All of this suggests that some monies are soon forthcoming. As Matt has indicated previously, the foreign players stepped forward literally days after Sanofi's termination notice. This means their interest persisted from at least mid-2014, so the probability is that a deal or two or three is pending, awaiting the full transfer of Afrezza from Sanofi to MNKD. Matt's objection to Olson's characterization, meantime, is strongly indicative of the probability that negotiations are ongoing to extract some money from Sanofi for its not living up to its legal obligations to use all reasonable efforts to sell Afrezza. All things considered, I think MNKD stock offers superb risk reward possibilities. Any announcement of a cash infusion, eliminating the fear of a near-term bankruptcy filing, would have the shares soaring. As such, I also think the notion of trading the stock, to take profits for those who bought at the lows, is rather silly. Beautifully said. I think you are right on the button with your analyses in this and several of your other recent posts. (I guess that means I agree with everything you are saying  ). But seriously, I strongly recommend people read your three posts in the thread entitled, "Take Away From Conf Call". I believe what you have said reveals the Truth of the events in the MNKD saga for the past couple of years. I think better days are on the horizon for MNKD and its incredible, super-rapid acting insulin. |
|
|
|
Post by hawaiiguy42 on Mar 15, 2016 18:43:52 GMT -5
Look at the Amgen stock chart while the he was the CCO. I would say he's a very good fit for Mannkind/Afrezza, etc. Do you really believe he was a catalyst for Amgen's stock price, a company with more than 17,000 employees? I surely do, chart plus tenure equals movement of stock. Name one of the other 17,000 employees who's tenure was the exact time frame. Look at the chart when he departed! |
|
).